Gunjan Shah
Overview
Explore the profile of Gunjan Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
757
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landsburg D, Frigault M, Heim M, Foley S, Hill B, Schofield G, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39924174
Background: Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2...
2.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
J Clin Oncol
. 2025 Jan;
:JCO2402424.
PMID: 39883889
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that...
3.
Shah G, Misra G, Nagavadiya V, Bhatt U
J Maxillofac Oral Surg
. 2024 Dec;
23(6):1419-1427.
PMID: 39618473
Introduction: Rhinocerebral mucormycosis (RCM) is devastating disease causing local morbidity as well mortality in some individuals. Many patients have lost their one side or bilateral maxilla and zygomatic bone. Patients...
4.
Rana D, Beladiya J, Sheth D, Kumar H, Jindal A, Shah G, et al.
Int J Pharm
. 2024 Oct;
666:124783.
PMID: 39353497
Dry eye syndrome (DES) presents a significant challenge in ophthalmic care, necessitating innovative approaches for effective management. This research article introduces a multifaceted strategy to address DES through the development...
5.
Hubbeling H, Leithner D, Silverman E, Flynn J, Devlin S, Shah G, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5083-5093.
PMID: 39259292
Purpose: Greater disease burden is a well-established predictor of poorer outcomes following chimeric antigen receptor T-cell (CAR T) therapy. Although bridging therapy (BT) is widely used between leukapheresis and CAR...
6.
Shaffer B, Brown S, Chinapen S, Mangold K, Lahoud O, Lopez-Jimenez F, et al.
Blood Adv
. 2024 Aug;
8(21):5603-5611.
PMID: 39158065
Artificial intelligence (AI)-enabled interpretation of electrocardiogram (ECG) images (AI-ECGs) can identify patterns predictive of future adverse cardiac events. We hypothesized that such an approach would provide prognostic information for the...
7.
Park J, Palomba M, Perica K, Devlin S, Shah G, Dahi P, et al.
Res Sq
. 2024 Jul;
PMID: 39011120
We designed a CD19-targeted CAR comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3z and 4-1BB/CD3z CARs. Here we report the first-in-human, phase 1 clinical...
8.
Stuver R, Mian A, Brown S, Devlin S, Caimi P, Chinapen S, et al.
Am J Hematol
. 2024 Mar;
99(6):1180-1183.
PMID: 38526002
No abstract available.
9.
Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa B, et al.
Res Sq
. 2024 Feb;
PMID: 38405866
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell...
10.
Shah G, Giralt S, Dahi P
Blood Rev
. 2023 Dec;
64:101162.
PMID: 38097487
Melphalan, has been a major component of myeloma therapy since the 1950s. In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen...